Abstract: A system and method for improving the functioning of a turbocharged diesel engine equipped with a cylinder deactivation system includes detecting when the turbocharged diesel engine is at risk of compressor surge, and then delaying the implementation of the cylinder deactivation. The delay may be a set period of time, or it may be determined by performing a set of instructions effective for estimating changes in intake manifold pressures over time if cylinders are deactivated, and then comparing the intake manifold pressure estimates to acceptable intake manifold pressure information. A formula for performing the required estimates is provided.

Abstract: A system and method for improving the functioning of a turbocharged diesel engine equipped with a cylinder deactivation system includes detecting when the turbocharged diesel engine is at risk of compressor surge, and then delaying the implementation of the cylinder deactivation. The delay may be a set period of time, or it may be determined by performing a set of instructions effective for estimating changes in intake manifold pressures over time if cylinders are deactivated, and then comparing the intake manifold pressure estimates to acceptable intake manifold pressure information. A formula for performing the required estimates is provided.

Abstract: The present invention provides genetically modified Pichia strains wherein at least one nucleic acid sequence encoding a functional gene product and/or at least one nucleic acid sequence necessary for expression of at least one functional gene product in said Pichia strain is genetically modified, wherein said gene product is responsible for proteolysis and/or glycosylation in said genetically modified Pichia strain. In particular, Pichia strains are provided wherein nucleic acid sequence encoding a functional gene product or expression of said gene product are genetically modified: PEP4, PRB1, YPS1, YPS2, YMP1, YMP2, YMP3 and PMT4.

Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.

Abstract: The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.

Abstract: The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.

Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.

Abstract: The present invention relates to methods of preventing glyconoylation of polypeptides produced in micororganisms.

Abstract: The present invention provides genetically modified Pichia strains wherein at least one nucleic acid sequence encoding a functional gene product and/or at least one nucleic acid sequence necessary for expression of at least one functional gene product in said Pichia strain is genetically modified, wherein said gene product is responsible for proteolysis and/or glycosylation in said genetically modified Pichia strain. In particular, Pichia strains are provided wherein nucleic acid sequence encoding a functional gene product or expression of said gene product are genetically modified: PEP4, PRB1, YPS1, YPS2, YMP1, YMP2, YMP3 and PMT4.

Abstract: The present invention relates to methods of preventing glyconoylation of polypeptides produced in micororganisms.

Abstract: This invention relates to fermentation processes for producing antibodies and other antigen binding compounds. Specifically, the present invention provides methods for increasing the specific productivity of an antibody produced in cell culture, increasing cell growth and increasing viability of cells in cell culture. Also provided are, expression stable, viable cell lines comprising DNA encoding adenovirus GAM1 and capable of producing a monoclonal antibody or fragment and/or variant thereof.

Abstract: The present invention provides methods for site-specifically integrating at least one first nucleic acid into a genome of at least one cell, comprising: transforming said genome with a reporter nucleic acid construct that is linked to a first att site; selecting at least one first transformed cell having at least one integrated reporter nucleic acid construct; introducing said at least one first nucleic acid and a homologous recombination mediating enzyme into said cell wherein said at least one first nucleic acid comprises at least one second att site that is complementary to said first att site; and maintaining said cell under conditions sufficient for said at least one first nucleic acid to integrate into said first att site producing at least one stably integrated cell.

Abstract: Erythropoietin receptor agonist and antagonist antibodies and their use in enhancing erythropoiesis are disclosed.

Abstract: Antibodies having reduced immunogenicity and methods for making them are disclosed.

Abstract: Chimeric, humanized and other IL-18 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Abstract: Chimeric, humanized and other IL-18 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Abstract: Chimeric, humanized and other RANK-L mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Abstract: Macaca cynomolgus IL18 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds which either agonize or antagonize Macaca cynomolgus IL18. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: cancer and auto-immune diseases.

Abstract: Antibodies having reduced immunogenicity and methods for making them are disclosed.